A Split-face Double-blind Randomized Placebo-controlled Trial of the Effectiveness of 5% Kaempferia parviflora Extract for Treatment of Melasma

Abstract

Background: Melasma is a common hyperpigmentary disorder that can cause significant psychosocial distress and quality of life impairments. Krachaidam (Kaempferia parviflora) extract is well known for its several methoxy flavones that has the anti-tyrosine activity and can inhibit the effect in melanin synthesis which can relief of melasma.

Objective: To research the effectiveness and satisfaction of 5% Kaempferia parviflora extract topical cream for the treatment of melasma.

Method: 16 volunteers, female of age between 30 and 65 years old who willingly wanted to get rid of their melasma were collected to participate in split-face double-blinded placebo-controlled trial for 8 weeks. 5% Kaempferia parviflora extract cream and placebo cream were instructed to apply twice daily in designated sides of the face for 8 weeks. Various parameters such as melasma evaluation by dermatologists, MASI score and melanin index were assessed at the start, 4^th and 8^th week respectively.

Result: Statistically significant results of reduction in MASI score (p-value <0.001) and reduction in mean melanin index (p-value<0.001) were shown for Kaempferia parviflora extract treated side. No side effects were observed throughout the study.

Conclusion: This study statistically demonstrated that Kaempferia parviflora extract reduced melanin production more than placebo cream when it is applied topically with no harmful side effects. So, 5% Kaempferia parviflora could be safe, effective and can be used as an alternative for the treatment of melasma.